THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD) Files An 8-K Results of Operations and Financial Condition

Item 2.02 (including Exhibit 99.1 hereto) shall not be deemed
filed for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or the Exchange Act, or otherwise
subject to the liabilities of that Section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended, or the
Securities Act. The information contained herein and in the
accompanying exhibit shall not be deemed to be incorporated by
reference into any filing under the Securities Act or the
Exchange Act, whether made before or after the date hereof,
regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits

Exhibits

About THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD)

Threshold Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. Evofosfamide is designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not in healthy tissues. Tarloxotinib is under investigation in two Phase II proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced NSCLC progressing on an EGFR TKI, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck. [18F]-HX4 is an investigational Positron Emission Tomography imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.

THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD) Recent Trading Information

THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD) closed its last trading session up +0.006 at 0.574 with 1,443,662 shares trading hands.